Macular Edema – Pipeline Review, H2 2017 – Research and Markets

Edema – Pipeline Review, H2 2017”
report has been added to Research
and Markets’

Macular Edema – Pipeline Review, H2 2017, provides comprehensive
information on the therapeutics under development for Macular Edema
(Ophthalmology), complete with analysis by stage of development, drug
target, mechanism of action (MoA), route of administration (RoA) and
molecule type. The guide covers the descriptive pharmacological action
of the therapeutics, its complete research and development history and
latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key
players involved in therapeutic development for Macular Edema and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase II, Preclinical and
Discovery stages are 1, 7 and 2 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and
tracking emerging players in the market and their portfolios, enhances
decision making capabilities and helps to create effective counter
strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Macular Edema – Overview
  3. Macular Edema – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Products under Development by Companies
  7. Macular Edema – Therapeutics Assessment
  8. Assessment by Target
  9. Assessment by Mechanism of Action
  10. Assessment by Route of Administration
  11. Assessment by Molecule Type
  12. Macular Edema – Companies Involved in Therapeutics Development
  • ActiveSite Pharmaceuticals Inc
  • Coherus BioSciences Inc
  • Lupin Ltd
  • Mabion SA
  • OMEICOS Therapeutics GmbH
  • Promedior Inc
  • Taiwan Liposome Company Ltd
  • Xbrane Biopharma AB

For more information about this report visit


Research and Markets
Laura Wood, Senior Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Topics: Cardiovascular
, Optical
Disorders Drugs